## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.22 indicates fundamental undervaluation. Quality metrics strong (ROE 136%, ROA 12%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-7.2% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($475.61)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Railway Pension Investments Ltd Buys 2,300 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251201T132122 | Bullish | Relevance: 99%
- Railway Pension Investments Ltd increased its stake in HCA Healthcare by 2.2%, acquiring an additional 2,300 shares. This brings their total holdings to 106,767 shares, valued at approximately $40.9 million. The article also details HCA Healthcare's recent financial performance, analyst ratings, and insider trading activity.

**2. J.W. Cole Advisors Inc. Sells 1,025 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251201T115111 | Somewhat-Bullish | Relevance: 99%
- J.W. Cole Advisors Inc. reduced its stake in HCA Healthcare by selling 1,025 shares, while other major institutional investors significantly increased their holdings. The article also details recent insider selling by two executive VPs, HCA Healthcare's strong financial performance beating analyst expectations, and a declared quarterly dividend. Analyst ratings for HCA Healthcare remain largely positive with a "Moderate Buy" consensus.

**3. Global Retirement Partners LLC Invests $433,000 in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251201T090903 | Bullish | Relevance: 99%
- Global Retirement Partners LLC recently invested $433,000 in HCA Healthcare, Inc. by acquiring 1,131 shares in Q2 2025. HCA Healthcare has shown strong financial performance, beating quarterly estimates with $6.96 EPS and $19.16 billion revenue, and analysts have set a "Moderate Buy" consensus with a $474.53 target price. The article also details other institutional investments, analyst ratings, stock performance, dividend announcements, and recent insider trading activities.

**4. F m Investments LLC Invests $4.08 Million in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251130T100618 | Bullish | Relevance: 99%
- F m Investments LLC initiated a new position in HCA Healthcare Inc. (NYSE:HCA) during the second quarter, acquiring 10,657 shares valued at approximately $4.08 million. This investment follows a period where HCA Healthcare exceeded Q3 earnings expectations, reporting $6.96 EPS against a $5.64 consensus and $19.16 billion in revenue, prompting a positive outlook with FY2025 guidance set at $27.00-$28.00 EPS. Despite some insider selling, the company has declared a quarterly dividend of $0.72 per share, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $474.53.

**5. HCA Healthcare, Inc. $HCA Shares Acquired by Dixon Mitchell Investment Counsel Inc.**
- Source: MarketBeat | 20251201T095435 | Bullish | Relevance: 99%
- Dixon Mitchell Investment Counsel Inc. significantly increased its stake in HCA Healthcare, making the stock its 29th largest holding. The article details HCA's strong Q3 earnings, positive FY2025 guidance, and a "Moderate Buy" consensus from analysts, alongside notable institutional investor activity and insider stock sales.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Wells Fargo | $431 | $412 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Heavy insider selling: $15M sold (4 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.22 suggests fair value with growth premium. Forward P/E 16.8x stretched relative to 8% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $109.7B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.22 |
| Forward P/E | 16.8 |
| Current P/E | 18.1 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 8.8% to 1.6% (-7.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.4pp (needs >4.0% for momentum thesis). MRS_5 (-2.3%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.4% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.85), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.57% (CS: 75) | Neutral |
| RSI_14 | 64.7 | Neutral |
| MACD Histogram | 0.85 | Bullish |
| vs SMA20 | 1.034x | Above |
| vs SMA50 | 1.103x | Above |
| vs SMA200 | 1.298x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $500.31
- **Stop Loss:** $475.61 (4.9% risk)
- **Target:** $549.71 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 40
- **Position Value:** $20,012.40
- **Portfolio %:** 20.01%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*